Arcus Biosciences, Inc. RCUS
18.80 USD +0.13 (+0.70%)
At closeNov 11, 2026, 4:00 PM EST
18.80 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
18.54 Day range 18.90
17.43 52-week range 31.74
- YTD
- -21.11%
- 1 year
- -7.34%
News
benzinga.com Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49 Leerink Partners analyst Daina Graybosch maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $46 to $49.
benzinga.com Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40 Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price target from $41 to $40.
benzinga.com Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45 Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and lowers the price target from $49 to $45.
benzinga.com Arcus Biosciences Q3 EPS $(1.00) Misses $(0.90) Estimate, Sales $9.000M Beat $8.305M Estimate Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.90) by 11.11 percent. This is a 21.26 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics…- benzinga.com Arcus Biosciences Commences Public Offering of Common Stock; Size Not Disclosed Arcus Biosciences, Inc. (NYSE:RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune…
benzinga.com Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50 Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $45 to $50.- benzinga.com Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41 Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $40 to $41.
benzinga.com Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49 Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $43 to $49.
benzinga.com Arcus Biosciences Reports Casdatifan Kidney Cancer Data, With Nearly 3-Year Median Overall Survival In Heavily Pretreated Patients And Phase 3 Trials Remain Pending Progression-free survival (PFS) for casdatifan plus anti-PD-1 in the first-line (1L) setting exceeded third-party benchmarks* for the approved anti-PD-1 plus anti-CTLA-4 regimen (ipilimumab plus…- benzinga.com William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating William Blair analyst Alethia Young initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Outperform rating.
- benzinga.com JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41 JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.